{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:24Z","timestamp":1771977624625,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,5,15]],"date-time":"2017-05-15T00:00:00Z","timestamp":1494806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,5,15]],"date-time":"2017-05-15T00:00:00Z","timestamp":1494806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We evaluated the efficacy and tolerability of chemotherapy in HIV-infected patients with diffuse large B-cell lymphoma (DLBCL) receiving CHOP\u2009\u00b1\u2009R (<jats:italic>n<\/jats:italic>\u2009=\u200917) or Burkitt lymphoma (BL) receiving CODOX-M\/IVAC\u2009\u00b1\u2009R (<jats:italic>n<\/jats:italic>\u2009=\u200915). The study was conducted in Beijing Ditan Hospital from January 2009 to August 2015. The following grade 4 adverse effects were observed in BL and DLBCL patients, respectively: neutropenia (80% versus 47.1%), anaemia (46.7% versus 5.9%), thrombocytopenia (53.3% versus 11.8%), bacterial pneumonia (33.3% versus 5.9%), and sepsis (20% versus 5.9%) (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). In the BL group, 10 (66.7%) patients died from treatment-related or tumour-related causes, 5 (33.3%) achieved complete response, 1 achieved partial response (6.7%), and 7 developed progressive disease. The 1-year overall survival and progression-free survival rates were 33.3%. Of the DLBCL patients, 3 (17.6%) died from treatment-related causes, 14 (82.4%) achieved complete response, and 3 had progressive disease. The 1-year overall survival and progression-free survival rates were 82.4%. The strongest risk factor for death was relapse between chemotherapy cycles (adjusted hazard ratio\u2009=\u200947.3; 95%CI, 4.2\u2013528.6, <jats:italic>p<\/jats:italic>\u2009=\u20090.002). Initiating antiretroviral therapy before chemotherapy failed to improve overall survival. DLBCL patients demonstrated good responses and survival outcomes, while BL patients could not tolerate chemotherapy due to more severe toxicity, and showed poor responses and survival outcomes.<\/jats:p>","DOI":"10.1038\/s41598-017-02086-4","type":"journal-article","created":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T11:30:58Z","timestamp":1494329458000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study"],"prefix":"10.1038","volume":"7","author":[{"given":"Jiang","family":"Xiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuxu","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guorui","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guiju","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,15]]},"reference":[{"key":"2086_CR1","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1158\/1055-9965.EPI-16-0273","volume":"25","author":"N Howlader","year":"2016","unstructured":"Howlader, N., Shiels, M. S., Mariotto, A. B. & Engels, E. A. Contributions of HIV to non-Hodgkin lymphoma mortality trends in the US. Cancer Epidemiol. Biomarkers Prev. \n                           25, 1289\u20131296 (2016).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"Suppl 2","key":"2086_CR2","first-page":"ii56","volume":"39","author":"Z Dou","year":"2010","unstructured":"Dou, Z. et al. Changing baseline characteristics among patients in the China National Free Antiretroviral Treatment Program, 2002\u201309. Int. J. Epidemiol. \n                           39(Suppl 2), ii56\u201364 (2010).","journal-title":"Int. J. Epidemiol."},{"key":"2086_CR3","doi-asserted-by":"publisher","first-page":"e75915","DOI":"10.1371\/journal.pone.0075915","volume":"8","author":"J Xiao","year":"2013","unstructured":"Xiao, J. et al. Spectrums of infectious complications and malignancies in HIV-infected patients in tertiary care hospital, China. PLoS One. \n                           8, e75915 (2013).","journal-title":"PLoS One."},{"key":"2086_CR4","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/j.1365-2141.2012.09046.x","volume":"157","author":"JM Ribera","year":"2012","unstructured":"Ribera, J. M. et al. Long-term follow-up of patients with HIV-related diffuse large B-cell lymphomas treated in a phase II study with rituximab and CHOP. Br. J. Haematol. \n                           157, 637\u2013639 (2012).","journal-title":"Br. J. Haematol."},{"key":"2086_CR5","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/QAD.0000000000000133","volume":"28","author":"R Coutinho","year":"2014","unstructured":"Coutinho, R. et al. HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era. AIDS \n                           28, 689\u2013697 (2014).","journal-title":"AIDS"},{"key":"2086_CR6","doi-asserted-by":"publisher","first-page":"735392","DOI":"10.1155\/2012\/735392","volume":"2012","author":"JA Rodrigo","year":"2012","unstructured":"Rodrigo, J. A. et al. HIV-associated Burkitt lymphoma: Good efficacy and tolerance of intensive chemotherapy including CODOX-M\/IVAC with or without rituximab in the HAART era. Adv. Hematol. \n                           2012, 735392 (2012).","journal-title":"Adv. Hematol."},{"key":"2086_CR7","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1093\/annonc\/mdf253","volume":"8","author":"GM Mead","year":"2002","unstructured":"Mead, G. M. et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt\u2019s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann. Oncol. \n                           8, 1264\u20131274 (2002).","journal-title":"Ann. Oncol."},{"key":"2086_CR8","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","volume":"121","author":"S Hu","year":"2013","unstructured":"Hu, S. et al. MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood \n                           121, 4021\u20134031 (2013).","journal-title":"Blood"},{"key":"2086_CR9","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1182\/blood-2007-09-111948","volume":"111","author":"LT Lam","year":"2008","unstructured":"Lam, L. T. et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood \n                           111, 3701\u20133713 (2008).","journal-title":"Blood"},{"key":"2086_CR10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans, C. P. et al. Conf\u0131rmation of the molecular classif\u0131cation of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood \n                           103, 275\u2013282 (2004).","journal-title":"Blood"},{"key":"2086_CR11","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1182\/blood-2008-06-164806","volume":"113","author":"N Asano","year":"2009","unstructured":"Asano, N. et al. Age-related Epstein Barr virus (EBV)-associated B-cell lymphoproliferative disorders: comparison with EBV-positive classic Hodgkin lymphoma in elderly patients. Blood \n                           113, 2629\u20132636 (2009).","journal-title":"Blood"},{"key":"2086_CR12","unstructured":"Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of infectious complications in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm. Rep. 58, 1\u2013207, quiz CE1-4 (2009)."},{"key":"2086_CR13","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s12185-013-1486-6","volume":"99","author":"S Inano","year":"2014","unstructured":"Inano, S. et al. Impact of high-dose chemotherapy and autologous transplantation as first-line therapy on the survival of high-risk diffuse large B cell lymphoma patients: a single-center study in Japan. Int J Hematol. \n                           99, 162\u2013168 (2014).","journal-title":"Int J Hematol."},{"key":"2086_CR14","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/bjh.12446","volume":"162","author":"F Hagemeister","year":"2013","unstructured":"Hagemeister, F. et al. Long term results of a phase 2 study of vincristine sulfate liposome injection substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. Br J Haematol. \n                           162, 631\u2013638 (2013).","journal-title":"Br J Haematol."},{"key":"2086_CR15","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents (2012) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http:\/\/aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf."},{"key":"2086_CR16","unstructured":"Zhang, F. editor. National Free HIV Antiretroviral Treatment Handbook. 3rd ed. Beijing, China. (People\u2019s Medical Publishing House, 2012) (Chinese)."},{"key":"2086_CR17","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson, B. D. et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J. Clin. Oncol. \n                           17, 1244\u20131253 (1999).","journal-title":"J. Clin. Oncol."},{"key":"2086_CR18","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1089\/aid.2015.0271","volume":"32","author":"J Xiao","year":"2016","unstructured":"Xiao, J. et al. Causes of death among patients infected with HIV at a tertiary care hospital in China: An observational cohort study. AIDS Res. Hum. Retroviruses. \n                           32, 782\u2013790 (2016).","journal-title":"AIDS Res. Hum. Retroviruses."},{"key":"2086_CR19","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.3109\/10428194.2012.679264","volume":"53","author":"F Cabanillas","year":"2012","unstructured":"Cabanillas, F. et al. Front-line immunochemotherapy for aggressive non-Hodgkin using dose-dense rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone plus granulocyte-macrophage colony stimulating factor and pegfilgrastim as support. Leuk. Lymphoma \n                           53, 1929\u20131933 (2012).","journal-title":"Leuk. Lymphoma"},{"key":"2086_CR20","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1093\/annonc\/mdq677","volume":"22","author":"JA Barnes","year":"2011","unstructured":"Barnes, J. A. et al. Evaluation of the addition of rituximab to CODOX-M\/IVAC for Burkitt\u2019s lymphoma: a retrospective analysis. Ann. Oncol. \n                           22, 1859\u20131864 (2011).","journal-title":"Ann. Oncol."},{"key":"2086_CR21","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","volume":"06","author":"LD Kaplan","year":"2005","unstructured":"Kaplan, L. D. et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab inpatients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood \n                           06, 1538\u20131543 (2005).","journal-title":"Blood"},{"key":"2086_CR22","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1093\/annonc\/mdt058","volume":"24","author":"T W\u00e4sterlid","year":"2013","unstructured":"W\u00e4sterlid, T. et al. Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group. Ann. Oncol. \n                           24, 1879\u20131886 (2013).","journal-title":"Ann. Oncol."},{"key":"2086_CR23","doi-asserted-by":"publisher","first-page":"R202","DOI":"10.1186\/cc10419","volume":"15","author":"HH Chiang","year":"2011","unstructured":"Chiang, H. H. et al. Admissions to intensive care unit of HIV-infected patients in the era of highly active antiretroviral therapy: etiology and prognostic factors. Crit. Care \n                           15, R202 (2011).","journal-title":"Crit. Care"},{"key":"2086_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1182\/blood-2015-01-623900","volume":"126","author":"A Noy","year":"2015","unstructured":"Noy, A. et al. AMC 048: modified CODOX-M\/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. Blood \n                           126, 160\u2013166 (2015).","journal-title":"Blood"},{"key":"2086_CR25","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.3324\/haematol.2013.086827","volume":"98","author":"T Intermesoli","year":"2013","unstructured":"Intermesoli, T. et al. High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program. Haematologica \n                           98, 1718\u20131725 (2013).","journal-title":"Haematologica"},{"key":"2086_CR26","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","volume":"369","author":"K Dunleavy","year":"2013","unstructured":"Dunleavy, K. et al. Low-intensity therapy in adults with Burkitt\u2019s lymphoma. N. Engl. J. Med. \n                           369, 1915\u20131925 (2013).","journal-title":"N. Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-02086-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-02086-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-02086-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T04:18:56Z","timestamp":1671769136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-02086-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,15]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["2086"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-02086-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,15]]},"assertion":[{"value":"23 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"1905"}}